Citations

Clear

9383 citation(s) found for "Thomas, PS".

Fourteen‐year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study
Mosley, Thomas H., Coker, Laura H., Study, Atherosclerosis Risk in Communities Study Brain MRI, Knopman, David S. , Mosley, Thomas H., Catellier, Diane , Study, Atherosclerosis Risk in Communities Study Brain MRI

Mayo Clinic

Alzheimer's & Dementia | April 13, 2009 | Volume: 5 | Issue: 3 | Pages: 207-214

10.1016/j.jalz.2009.01.027 | PMID 19362884 Get It

BackgroundStrokes, vascular risk factors, and apolipoprotein E (APOE) genotype are associated with cognitive decline in the elderly, but definitive evidence that these affect cognition as early as middle age is limited.ObjectiveWe describe the relationships of APOE genotype, stroke, and vascular risk factors with cognitive change over a 14‐year follow‐up in the Atherosclerosis Risk in Communities (ARIC) Study cohort recruited while in middle age.MethodsParticipants included a subset of the ARIC Study who underwent assessments of cognitive function and vascular risk factors. Four cognitive assessments were performed between 1990–1992 and 2004–2006. Cognitive assessments included the Delayed Word Recall (DWR) Test, the Digit Symbol Substitution (DSS) Test, and the Word Fluency (WF) Test. Vascular risk factors were assessed during the baseline visit in 1990–1992. Incident stroke was recorded over the 14 years of follow‐up.ResultsThere were 1130 participants (mean age, 59 ± 4.3 [SD] years; 62% women; 52% African‐American) with longitudinal data. In multivariate, random‐effects linear models adjusted for age, education, gender, and race, the risk factors diabetes and APOE ɛ4 genotype were independently associated with a decline in performance on the DSS test (both P < .005), whereas hypertension and stroke were not. For DWR, stroke and APOE ɛ4 genotype were independent predictors of decline (both P < .001). For the WF test, metabolic syndrome, hypertension, and stroke were independently associated with decline (all P < .005). No evidence of differential effects of risk factors on cognitive decline by race, gender, or interactions between risk factors was found.ConclusionsThe vascular risk factors diabetes and hypertension, a history of stroke itself, and APOE ɛ4 genotype independently contribute to cognitive decline in late middle age and early elderly years.
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
Stadtmauer, Edward A. , Nademanee, Auayporn, Micallef, Ivana N. , Stiff, Patrick J. , Hosing, Chitra , Früehauf, Stefan, Horwitz, Mitchell E. , Cooper, Dennis , Bridger, Gary, Calandra, Gary, Investigators, for the 3102, DiPersio, John F. , Kaufman, Jonathan L. , Maziarz, Richard Thomas , Investigators, for the 3102

Mayo Clinic

Blood | April 10, 2009 | Volume: 113 | Issue: 23 | Pages: 5720-5726

10.1182/blood-2008-08-174946 | PMID 19363221 Get It

Abstract This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in mobilizing hematopoietic stem cells in patients with multiple myeloma. Patients received G-CSF (10 μg/kg) subcutaneously daily for up to 8 days. Beginning on day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 μg/kg) or placebo subcutaneously. Starting on day 5, patients began daily apheresis for up to 4 days or until more than or equal to 6 × 106 CD34+ cells/kg were collected. The primary endpoint was the percentage of patients who collected more than or equal to 6 × 106 CD34+ cells/kg in less than or equal to 2 aphereses. A total of 106 of 148 (71.6%) patients in the plerixafor group and 53 of 154 (34.4%) patients in the placebo group met the primary endpoint (P < .001). A total of 54% of plerixafor-treated patients reached target after one apheresis, whereas 56% of the placebo-treated patients required 4 aphereses to reach target. The most common adverse events related to plerixafor were gastrointestinal disorders and injection site reactions. Plerixafor and G-CSF were well tolerated, and significantly more patients collected the optimal CD34+ cell/kg target for transplantation earlier compared with G-CSF alone. This study is registered at www.clinicaltrials.gov as #NCT00103662.
Intraoperative Endoleak During EVAR: Frequency, Nature, and Significance
Sampaio, Sérgio , Shin, Susanna, Panneton, Jean M. , Andrews, James C., Bower, Thomas C., Cherry, Kenneth J., Duncan, Audra A. , Kalra, Manju , Gloviczki, Péter , Gloviczki, Péter

Mayo Clinic

Vascular and Endovascular Surgery | April 7, 2009 | Volume: 43 | Issue: 4 | Pages: 352-359

10.1177/1538574409333581 | PMID 19351648 Get It

Objective: Endoleaks are critical complications of endovascular abdominal aortic aneurysm repair (EVAR). This study sought to determine the frequency and nature of intraoperative endoleaks and their impact on postoperative endoleak-related events. Methods: A retrospective chart review was performed of all patients who underwent EVAR at our institution. The impact of intraoperative endoleaks on postoperative endoleak rates and endoleak-related reintervention rates were assessed. Results: From December 18, 1996, to May 21, 2003, 241 patients underwent EVAR. An endoleak was observed during 126 (52.3%) procedures. Type I endoleaks were observed in 63 (26.1%) cases: 35 proximal and 31 distal endoleaks (3 cases at both attachments). Angioplasty, additional cuff placement, or stenting corrected 59 (89.4%) of these endoleaks. A total of 71 type II intraoperative endoleaks (29.5%) and 8 type IV endoleaks (3.3%) were observed without any attempted corrective maneuvers. Ten type III endoleaks (4.2%) occurred but all resolved with angioplasty or additional cuff placement. In all, 86 (35.7%) endoleaks persisted on completion angiogram. Patients with a type I or type II intraoperative endoleak were more likely to have an endoleak at 1.5 years (31.4% vs. 21.6%, P = .018). Reinterventions were required more often after an intraoperative type I endoleak (10% vs. 4%, P = .003). Patients with intraoperative endoleaks demonstrated a trend toward less postoperative aneurysm diameter reduction at 2 years (43.8% vs. 74.5%, P = .104). Conclusion: The presence of a type I or a type II endoleak during EVAR significantly increases the likelihood of a postoperative endoleak and should prompt a high degree of suspicion during follow-up.
Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831
Halyard, Michele Y. , Pisansky, Thomas M. , Dueck, Amylou C. , Pierce, Lori J. , Solin, Larry, Marks, L.B., Davidson, Nancy E. , Martino, Silvana, Kutteh, Leila A., Dakhil, Shaker R. , Perez, Edith A. , Suman, Vera J. , Kaufman, Peter A. , Dueck, A. C.

Mayo Clinic

Journal of Clinical Oncology | April 6, 2009 | Volume: 27 | Issue: 16 | Pages: 2638-2644

10.1200/jco.2008.17.9549 | PMID 19349549 Get It

Purpose To assess whether trastuzumab (H) with radiotherapy (RT) increases adverse events (AEs) after breast-conserving surgery or mastectomy. Patients and Methods Patients with early-stage resected human epidermal growth factor receptor 2 (HER-2) –positive breast cancer (BC) were randomly assigned to doxorubicin (A) and cyclophosphamide (C), followed by weekly paclitaxel (T; AC-T-H or AC-TH-H). RT criteria (with or without nodal RT) were postlumpectomy breast or (optional) postmastectomy chest wall. RT of internal mammary nodes was prohibited. RT commenced within 5 weeks after T, concurrently with H. Analysis included 1,503 irradiated patients for RT-associated AEs across treatment arms. Rates of cardiac events (CEs) with and without RT were compared within arms. Results No significant differences among arms were found in incidence of acute skin reaction, pneumonitis, dyspnea, cough, dysphagia, or neutropenia. A significant difference occurred in incidence of leukopenia, with higher rates for AC-T-H versus AC-T (odds ratio = 1.89; 95% CI, 1.25 to 2.88). At a median follow-up of 3.7 years (range, 0 to 6.5 years), RT with H did not increase relative frequency of CEs regardless of treatment side. The cumulative incidence of CEs with AC-T-H was 2.7% with or without RT. With AC-TH-H, the cumulative incidence was 1.7% v 5.9% with or without RT, respectively. Conclusion Concurrent adjuvant RT and H for early-stage BC was not associated with increased acute AEs. Further follow-up is required to assess late AEs.
Neurotrophic Factor–Expressing Mesenchymal Stem Cells Survive Transplantation into the Contused Spinal Cord Without Differentiating into Neural Cells
Rooney, Gemma E., McMahon, Siobhán S. , Ritter, Thomas , Moran, Cathal J., Madigan, Nicolas N. , Flügel, Alexander , Dockery, Peter , O’Brien, Timothy , Howard, Linda , Windebank, Anthony J. , Barry, Frank , García, Yolanda García

Mayo Clinic

Tissue Engineering Part A | March 31, 2009 | Volume: 15 | Issue: 10 | Pages: 3049-3059

10.1089/ten.tea.2009.0045 | PMID 19335061 Get It

Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis
Loprinzi, Charles L. , Sloan, Jeff A. , Slack, Rebecca, Iyengar, Malini, Diekmann, Brent, Kimmick, Gretchen , Lovato, James , Gordon, Paul , Pandya, Kishan J., Guttuso, Thomas , Barton, Debra L. , Novotny, Paul J. , Stearns, Vered

Mayo Clinic

Journal of Clinical Oncology | March 31, 2009 | Volume: 27 | Issue: 17 | Pages: 2831-2837

10.1200/jco.2008.19.6253 | PMID 19332723 Get It

Purpose Nonhormonal treatment options have been investigated as treatments for hot flashes, a major clinical problem in many women. Starting in 2000, a series of 10 individual double-blind placebo-controlled studies has evaluated newer antidepressants and gabapentin for treating hot flashes. This current project was developed to conduct an individual patient pooled analysis of the data from these published clinical trials. Patients and Methods Individual patient data were collected from the various study investigators who published their study results between 2000 and 2007. Between-study heterogeneity for study characteristics and patient populations was tested via χ2 tests before a pooled analysis. The primary end point, the change in hot flash activity from baseline to week 4, for each agent was calculated via both weighted and unweighted approaches, using the size of the study as the weight. Basic summary statistics were produced for hot flash score and frequency using the following three statistics: raw change, percent reduction, and whether or not a 50% reduction was achieved. Results This study included seven trials of newer antidepressants and three trials of gabapentin. The optimal doses (defined by individual study results) of the newer antidepressants paroxetine, venlafaxine, fluoxetine, and sertraline decreased hot flash scores by 41%, 33%, 13%, and 3% to 18% compared with the corresponding placebo arms, respectively. The three gabapentin trials decreased hot flashes by 35% to 38% compared with the corresponding placebo arms. Conclusion Some newer antidepressants and gabapentin, within 4 weeks of therapy initiation, decrease hot flashes more than placebo.
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Kapoor, Prashant , Kumar, Shaji , Fonseca, Rafaël , Lacy, Martha Q. , Hayman, Suzanne R. , Dispenzieri, Angela , Bergsagel, P. Leif , Dalton, Robert J., Dingli, David , Reeder, Craig B. , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Stewart, A. Keith, Kyle, Robert A. , Greipp, Philip R., Rajkumar, S. Vincent , Witzig, Thomas E. , Buadi, Francis K. , Gertz, Morie A. , Mıkhael, Joseph , Roy, Vivek , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | March 26, 2009 | Volume: 114 | Issue: 3 | Pages: 518-521

10.1182/blood-2009-01-202010 | PMID 19324902 Get It

Abstract The outcome of patients with multiple myeloma is dictated primarily by cytogenetic abnormalities and proliferative capacity of plasma cells. We studied the outcome after initial therapy with lenalidomide-dexamethasone among 100 newly diagnosed patients, risk-stratified by genetic abnormalities and plasma cell labeling index. A total of 16% had high-risk multiple myeloma, defined by the presence of hypodiploidy, del(13q) by metaphase cytogenetics, del(17p), IgH translocations [t(4;14), or t(14;16)] or plasma cell labeling index more than or equal to 3%. Response rates were 81% vs 89% in the high-risk and standard-risk groups, respectively. The median progression-free survival was shorter in the high-risk group (18.5 vs 36.5 months, P < .001), but overall survival was comparable. Because of unavailability of all tests for every patient, we separately analyzed 55 stringently classified patients, and the results were similar. In conclusion, high-risk patients achieve less durable responses with lenalidomide-dexamethasone compared with standard-risk patients; no significant differences in overall survival are apparent so far. These results need confirmation in larger, prospectively designed studies.
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of rapamycin activation
Dillon, Stacey R. , Ziesmer, Steven C., Feldman, Andrew L. , Ansell, Stephen M. , Cerhan, James R. , Novak, Anne J. , Gupta, Mamta , Witzig, Thomas E. , Feldman, Andrew L , Cerhan, James R

Mayo Clinic

Blood | March 26, 2009 | Volume: 113 | Issue: 21 | Pages: 5206-5216

10.1182/blood-2008-09-179762 | PMID 19321861 Get It

Abstract A proliferation-inducing ligand (APRIL), as well as its receptors transmembrane activator and calcium-modulating cyclophilin ligand (CAML) interactor (TACI) and B-cell maturation antigen (BCMA), has been shown to be important in B-cell biology, and overexpression of APRIL in mice results in development of lymphoma. Limited data are available on APRIL-specific signaling responses, but knockout models suggest that signaling through TACI is critical to B-cell homeostasis. To better understand the mechanism by which APRIL exerts its effects and how it may contribute to lymphomagenesis, we sought to characterize the outcome of APRIL-TACI interactions. In support of murine studies, we find that APRIL induces proliferation of human patient follicular lymphoma (FL) B cells in a TACI-dependent manner. This study also shows that APRIL is expressed within the tumor microenvironment and that, upon engagement with TACI, APRIL mediates activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Activation of PI3K via APRIL results in phosphorylation of Akt and mammalian target of rapamycin (mTOR) and the mTOR-specific substrates p70S6 kinase and 4E-binding protein 1 in a TACI-dependent manner. APRIL-mediated signaling also results in phosphorylation of Rb and up-regulation of cyclin D1. These studies are the first to characterize APRIL-TACI–specific signaling and suggest a role for this ligand-receptor pair in FL B-cell growth.
Comparison of required operating forces between floor-based and overhead-mounted patient lifting devices
Rice, Martin S., Woolley, Sandra M., Waters, Thomas

Mayo Clinic

Ergonomics | March 23, 2009 | Volume: 52 | Issue: 1 | Pages: 112-120

10.1080/00140130802481123 | PMID 19308824 Get It

Elevated serum immunoglobulin E (IgE): When to suspect hyper-IgE syndrome—A 10-year pediatric tertiary care center experience
Joshi, Avni Y. , Boyce, Thomas G. , Hagan, John B., Park, Miguel A., Abraham, Roshini S. , Iyer, Vivek

Mayo Clinic

Allergy and Asthma Proceedings | March 19, 2009 | Volume: 30 | Issue: 1 | Pages: 23-27

10.2500/aap.2009.30.3193 | PMID 19331717 Get It